Document 0106
 DOCN  M9480106
 TI    Effect of MTP-PE liposomes and interleukin-7 on induction of antibody
       and cell-mediated immune responses to a recombinant HIV-envelope
       protein.
 DT    9410
 AU    Bui T; Dykers T; Hu SL; Faltynek CR; Ho RJ; Department of Pharmaceutics,
       University of Washington, Seattle; 98195.
 SO    J Acquir Immune Defic Syndr. 1994 Aug;7(8):799-806. Unique Identifier :
       AIDSLINE MED/94293161
 AB    We investigated the ability of human recombinant interleukin-7 (IL-7) to
       enhance the immune responses of mice vaccinated with either the
       alum-associated or liposome-formulated recombinant human
       immunodeficiency virus (HIV)-envelope protein, env-2-3SF2 (a
       nonglycosylated denatured gp 120 of HIV-1SF2 produced in genetically
       engineered yeast). Pathogen-free (C3H) mice were vaccinated on days 0,
       14, and 28 with 10 micrograms of either the alum-associated env-2-3SF2
       or liposome-formulated env-2-3SF2, both containing a lipophylic muramyl
       tripeptide, MTP-PE. Liposome-formulated IL-7 (5 micrograms/mouse) or
       empty liposomes were given on days 7, 14, 21, and 28. Antibody response
       against the immunized antigen, evaluated on day 21 and day 35 or 42,
       showed that liposome-formulated antigen induced higher antibody titer
       than did alum-associated antigen, and these antibody responses can be
       enhanced by concurrent administration of IL-7 liposomes. Spleen cells
       were harvested on day 21 and day 35 or 42 to evaluate cytotoxic T
       lymphocyte responses directed against autologous cells infected with
       vaccinia virus-expressing HIV-envelope protein. Mice treated with
       liposome-formulated antigen expressed the highest cytotoxic t-lymphocyte
       (CTL) activity, regardless of whether IL-7 liposome was given as an
       immune potentiator. In contrast, spleen cells from mice vaccinated with
       alum-associated antigen exhibited minimal CTL response, which was
       enhanced by concurrent IL-7 liposome treatment. Collectively, IL-7
       liposome treatment enhanced the antibody production of the
       alum-associated or liposome-formulated env-2-3SF2, whereas its
       enhancement of CTL activity was detected only in mice vaccinated with
       alum-associated antigen.
 DE    Acetylmuramyl-Alanyl-Isoglutamine/*ANALOGS & DERIVATIVES/
       ADMINISTRATION & DOSAGE/IMMUNOLOGY  *Adjuvants,
       Immunologic/ADMINISTRATION & DOSAGE  Animal  AIDS
       Vaccines/ADMINISTRATION & DOSAGE/*IMMUNOLOGY  Cytotoxicity, Immunologic
       Drug Carriers  Gene Products, env/*IMMUNOLOGY  HIV
       Antibodies/BIOSYNTHESIS  HIV-1/*IMMUNOLOGY  Interleukin-7/ADMINISTRATION
       & DOSAGE/*IMMUNOLOGY  Liposomes  Mice  Mice, Inbred C3H
       Phosphatidylethanolamines/ADMINISTRATION & DOSAGE/*IMMUNOLOGY
       Recombinant Proteins/ADMINISTRATION & DOSAGE/IMMUNOLOGY  Specific
       Pathogen-Free Organisms  Support, U.S. Gov't, P.H.S.  T-Lymphocytes,
       Cytotoxic/IMMUNOLOGY  Vaccines, Synthetic/ADMINISTRATION &
       DOSAGE/IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).